LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Tozasertib | 1.11 | uM | LJP5 | 2 | B15 | 72 | hr | 868 | 1011 | 3505 | 0.2884 | 0.0786 |
MDA-MB-231 | Tozasertib | 1.11 | uM | LJP5 | 3 | B15 | 72 | hr | 868 | 1160 | 3440 | 0.3372 | 0.1571 |
MDA-MB-231 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 868 | 1201 | 3286 | 0.3655 | 0.1841 |
MDA-MB-231 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 868 | 1089 | 3505 | 0.3107 | 0.1192 |
MDA-MB-231 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 868 | 1094 | 3440 | 0.3180 | 0.1235 |
MDA-MB-231 | Tozasertib | 10 | uM | LJP5 | 1 | B13 | 72 | hr | 868 | 1345 | 3286 | 0.4093 | 0.2561 |
MDA-MB-231 | Tozasertib | 10 | uM | LJP5 | 2 | B13 | 72 | hr | 868 | 1306 | 3505 | 0.3726 | 0.2249 |
MDA-MB-231 | Tozasertib | 10 | uM | LJP5 | 3 | B13 | 72 | hr | 868 | 1397 | 3440 | 0.4061 | 0.2706 |
MDA-MB-231 | Imatinib | 0.04 | uM | LJP6 | 1 | N18 | 72 | hr | 868 | 3749 | 3429 | 1.0931 | 1.0918 |
MDA-MB-231 | Imatinib | 0.04 | uM | LJP6 | 2 | N18 | 72 | hr | 868 | 3984 | 3652 | 1.0909 | 1.0857 |
MDA-MB-231 | Imatinib | 0.04 | uM | LJP6 | 3 | N18 | 72 | hr | 868 | 3770 | 3587 | 1.0509 | 1.0491 |
MDA-MB-231 | Imatinib | 0.12 | uM | LJP6 | 1 | N17 | 72 | hr | 868 | 3640 | 3429 | 1.0613 | 1.0609 |
MDA-MB-231 | Imatinib | 0.12 | uM | LJP6 | 2 | N17 | 72 | hr | 868 | 3673 | 3652 | 1.0058 | 1.0055 |
MDA-MB-231 | Imatinib | 0.12 | uM | LJP6 | 3 | N17 | 72 | hr | 868 | 3746 | 3587 | 1.0442 | 1.0428 |
MDA-MB-231 | Imatinib | 0.37 | uM | LJP6 | 1 | N16 | 72 | hr | 868 | 3676 | 3429 | 1.0718 | 1.0712 |
MDA-MB-231 | Imatinib | 0.37 | uM | LJP6 | 2 | N16 | 72 | hr | 868 | 3808 | 3652 | 1.0427 | 1.0408 |
MDA-MB-231 | Imatinib | 0.37 | uM | LJP6 | 3 | N16 | 72 | hr | 868 | 3852 | 3587 | 1.0738 | 1.0708 |
MDA-MB-231 | Imatinib | 1.11 | uM | LJP6 | 1 | N15 | 72 | hr | 868 | 3473 | 3429 | 1.0126 | 1.0127 |
MDA-MB-231 | Imatinib | 1.11 | uM | LJP6 | 2 | N15 | 72 | hr | 868 | 3870 | 3652 | 1.0597 | 1.0567 |
MDA-MB-231 | Imatinib | 1.11 | uM | LJP6 | 3 | N15 | 72 | hr | 868 | 3927 | 3587 | 1.0947 | 1.0904 |
MDA-MB-231 | Imatinib | 3.33 | uM | LJP6 | 1 | N14 | 72 | hr | 868 | 3559 | 3429 | 1.0377 | 1.0377 |
MDA-MB-231 | Imatinib | 3.33 | uM | LJP6 | 2 | N14 | 72 | hr | 868 | 3823 | 3652 | 1.0468 | 1.0446 |
MDA-MB-231 | Imatinib | 3.33 | uM | LJP6 | 3 | N14 | 72 | hr | 868 | 3710 | 3587 | 1.0342 | 1.0331 |
MDA-MB-231 | Imatinib | 10 | uM | LJP6 | 1 | N13 | 72 | hr | 868 | 3242 | 3429 | 0.9453 | 0.9440 |
MDA-MB-231 | Imatinib | 10 | uM | LJP6 | 2 | N13 | 72 | hr | 868 | 3278 | 3652 | 0.8976 | 0.8984 |